Table 3.
Frequencies of methylated genes, CTC and combinations in association to clinico-pathological features.
| Number of Methylation PositivePatients | Number of CTC Positive Patients | Methylation OR CTC pos. | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables | APC | RASSF1A | GSTP1 | ESR1 |
Min-1 ≥ 1 × pos. (APC or RASSF1A, GSTP1) |
Min-2 ≥ 2 × pos. (APC or RASSF1A, GSTP1) |
CTC-2 ≥ 1× pos CTC (EPCAM or Muc1) |
CTC-4 ≥ 1× pos CTC (EPCAM, Muc1 MGB1 or SPDEF) |
COMBI Min-2 or CTC-2 |
| ER | |||||||||
| Positive | 14/61 | 14/61 | 9/55 | 21/61 | 21/54 | 9/54 | 6/47 | 9/41 | 13/46 |
| Negative | 5/11 | 3/11 | 3/11 | 3/11 | 7/11 | 3/11 | 3/10 | 3/9 | 5/10 |
| PR | |||||||||
| Positive | 12/48 | 11/48 | 6/42 | 16/48 | 16/41 | 6/41 | 6/36 | 9/30 | 10/33 |
| Negative | 8/26 | 8/26 | 6/25 | 12/26 | 13/25 | 7/25 | 3/23 | 3/20 | 9/24 |
| Her2/neu | |||||||||
| Negative | 11/46 | 8/46 | 4/44 | 14/46 | 17/43 | 3/43 | 5/33 | 6/28 | 8/34 |
| Positive | 7/20 | 7/20 | 7/17 | 12/20 | 9/17 | 7/17 | 4/18 | 4/16 | 8/17 |
| **p = 0.003 | *p = 0.024 | **p = 0.001 | p = 0.088 | ||||||
| CA15.3 | |||||||||
| Negative | 9/52 | 12/52 | 7/50 | 20/52 | 20/49 | 6/49 | 5/50 | 7/43 | 10/48 |
| Positive | 8/10 | 4/10 | 4/10 | 4/10 | 8/10 | 5/10 | 6/9 | 7/8 | 8/9 |
| **p = 0.000 | *p = 0.024 | **p = 0.005 | **p = 0.000 | **p = 0.000 | **p = 0.000 | ||||
| Tumor size | |||||||||
| T1+T2 | 16/61 | 11/61 | 6/57 | 21/61 | 22/56 | 6/56 | 8/49 | 11/41 | 12/48 |
| T3+T4 | 5/13 | 6/13 | 6/11 | 7/13 | 9/11 | 5/11 | 3/10 | 3/10 | 6/10 |
| *p = 0.029 | **p = 0.000 | **p = 0.010 | **p = 0.004 | *p = 0.030 | |||||
| LN State | |||||||||
| Negative | 7/32 | 8/32 | 3/32 | 11/32 | 13/31 | 4/31 | 2/28 | 5/26 | 6/27 |
| Positive | 15/43 | 13/43 | 10/37 | 18/43 | 19/37 | 10/37 | 9/31 | 9/26 | 15/32 |
| *p = 0.031 | *p = 0.049 | ||||||||
| M State | |||||||||
| Negative | 6/35 | 7/35 | 4/33 | 13/35 | 11/32 | 4/32 | 2/29 | 4/24 | 5/28 |
| Positive | 14/25 | 11/25 | 5/21 | 9/25 | 14/21 | 9/21 | 7/19 | 8/18 | 14/21 |
| **p = 0.002 | *p = 0.046 | *p = 0.021 | *p = 0.012 | **p = 0.009 | *p = 0.049 | **p = 0.001 | |||
| AJCC-lndex | |||||||||
| 0+ I | 3/20 | 5/20 | 2/19 | 10/20 | 6/19 | 2/19 | 0/18 | 0/16 | 2/18 |
| II | 2/22 | 0/22 | 1/20 | 6/22 | 2/19 | 0/19 | 2/15 | 4/14 | 2/13 |
| III | 5/12 | 4/12 | 4/12 | 6/12 | 9/12 | 3/12 | 3/10 | 3/7 | 4/11 |
| IV | 12/23 | 10/23 | 5/19 | 8/23 | 12/19 | 8/19 | 7/18 | 8/17 | 13/19 |
| **p = 0.001 | *p = 0.031 | *p = 0.022 | **p = 0.003 | **p = 0.002 | **p = 0.003 | **p = 0.001 | |||
| Disease status | |||||||||
| FD | 13/64 | 13/64 | 10/59 | 26/64 | 23/58 | 9/58 | 7/49 | 9/44 | 13/48 |
| RD | 10/19 | 8/19 | 3/15 | 5/19 | 11/15 | 5/15 | 5/13 | 6/11 | 9/14 |
| **p = 0.006 | *p = 0.020 | *p = 0.050 | *p = 0.023 | *p = 0.023 | |||||
| Group | |||||||||
| Tumor | 29% 25/85 | 26% 22/85 | 18% 14/76 | 38% 32/85 | 48% 36/75 | 20% 15/75 | 19% 12/63 | 27% 15/55 | 35% 22/62 |
| Control | 2/22 | 5/22 | 1/16 | 5/22 | 6/16 | 2/16 | 2/14 | 2/14 | 8/30 |
| *p = 0.050 | |||||||||
p < 0.05; ** p < 0.005 high significant